Blog

Inside Metabolon Lab Operations: Scaling Metabolomics with Quality and Reproducibility: An interview with Leane Woody, Director of Lab Operations at Metabolon

Leane Woody, MBA

What do you do at Metabolon? 

As Director of Operations at Metabolon, I sit at the intersection of science and execution.  My responsibility is to ensure we can deliver highly complex metabolomics work at scale without compromising quality, reproducibility, or speed.  At the end of the day, our teams are turning biological samples into actionable biochemical insights, and my role is to ensure the operational foundation is strong enough to support that consistently. 

What makes that especially meaningful is the role metabolomics plays in multiomic science.  Metabolomics is valuable as a standalone capability, but it is even more powerful as part of a broader effort to understand integrated biological systems.  Supporting that kind of work at scale takes more than great technology.  It requires real operational discipline. 

What does that look like in practice? 

It starts with building an operation that is designed for both scale and scientific rigor.  We process hundreds of thousands of samples each year on LC/MS platforms, so every part of the system has to be intentional.  That includes how we schedule work, manage capacity, monitor instrument performance, and identify issues before they become problems. 

We rely heavily on clearly defined KPIs to track things like rework, uptime, throughput, and turnaround time.  Those metrics give us real-time visibility into how the operation is performing and where we may need to intervene.  The goal is not just to keep the system moving.  It is to keep it moving while protecting data quality and scientific integrity. 

How do you maintain quality while operating at that level of scale? 

For me, quality has to be built into the system rather than inspected at the end.  That means robust LC/MS methods, strong controls, automated liquid handling (which reduces risk), and QC systems that help us detect variability or drift before it impacts results. 

It also means thinking beyond basic operational efficiency.  In a multiomics environment, consistency matters enormously because the data must stand up not only on its own but also in combination with other omic datasets.  If you lack reproducibility and stability over time, integration becomes much more difficult, and the biological signal becomes harder to interpret with confidence. 

What role does operational excellence play in Metabolon’s broader strategy? 

It is foundational.  Operational excellence enables us to scale without sacrificing the quality our partners expect from us.  It is also what gives us confidence that data generated today can be compared reliably with data generated months later or across thousands of samples. 

That consistency is a strategic advantage.  It supports stronger science, better integration across omics, and faster delivery of results.  It also gives us the ability to grow thoughtfully.  As we expand our offerings, we do it on top of the same operational backbone, with the same expectations around method standardization, quality control, and performance oversight. 

What kind of outcomes has that approach delivered? 

We have seen very tangible results.  We have reduced rework to below 3 percent.  This is a strong operational metric, but what matters more is what it enables.  This improves data consistency, strengthens downstream analysis, and helps us deliver results to partners more efficiently. 

At scale, even small variability becomes visible.  That is why I believe operations in this kind of environment have to be predictive, not reactive.  Preventive maintenance, volume-based servicing, and continuous performance monitoring are all part of making sure the platform remains stable as demand grows. 

How do you think about growth and innovation? 

Growth is important, but not at the expense of reproducibility.  Innovation is important, but not if it weakens the standards that made the platform trusted in the first place.  My view is that every new capability has to be built on the same disciplined foundation. 

That means growth and diversification should reinforce excellence, not dilute it.  When the operational backbone is strong, you can expand with confidence.  You can support more customers, more samples, and more scientific complexity while preserving the quality and reliability that matter most to Metabolon’s customers. 

Metabolon
Our team is made up of over 45 PhDs, has been published 4,000+ times, and is committed to hard work, excellence, and success through collaboration. With over 15,000 projects, Metabolon has been a trusted partner of researchers for over 25 years.

Topics

Share this article

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.